Press release

Siemens Healthineers names new candidates for election to the supervisory board

Published on November 25, 2022
<ul><li><strong>Sarena Lin and Dow Wilson nominated to contribute their global management experience and expertise&nbsp;</strong></li><li><strong>Supervisory board recommends renewing Ralf P. Thomas’ mandate as chair&nbsp;</strong></li></ul><p>The supervisory board of Siemens Healthineers AG is proposing four new members for election by the annual shareholders' meeting (ASM) on February 15, 2023. <strong>Dow Wilson</strong>, former CEO of Varian, <strong>Sarena Lin</strong>, member of the Board of Management of Bayer AG, <strong>Peter Körte</strong>, Chief Technology and Strategy Officer at Siemens AG, as well as <strong>Veronika Bienert</strong>, CEO of Siemens Financial Services, have been nominated as new members.&nbsp;</p><p>The supervisory board recommends <strong>Prof. Dr. Ralf P. Thomas</strong> to continue as chair. The chair will be elected by the new supervisory board in its constituent meeting following the ASM.&nbsp;</p><p>The proposed new members of the Siemens Healthineers supervisory board reflect the company’s international standing and commitment to diversity, with 40 percent of the proposed new board being women. These proposals are made on the recommendation of the supervisory board’s presiding committee.&nbsp;</p><p>Based on 35 years of experience in the healthcare industry, Dow Wilson would enrich the supervisory board with his expertise in cancer care and global business management. After spending 20 years of his career with General Electric, he held key executive positions at Varian, leading the company from 2012 until its successful combination with Siemens Healthineers in 2021.&nbsp;</p><p>As Chief Transformation and Talent Officer and Labor Director of Bayer AG, Sarena Lin is responsible for human resources, strategy and business consulting. Previously, she held several executive positions. In a previous role at Elanco Animal Health, she was instrumental in the acquisition and integration of Bayer’s Animal Health business. While working at McKinsey in the United States and Taiwan, she gained rich advisory experience and a deep understanding of the international and Asian business landscapes.&nbsp;</p><p>“Over the past five years, the entire supervisory board has supported Siemens Healthineers in growing into a bigger and more relevant healthcare company with the acquisition of Varian and the inclusion in the DAX-40 as just two major milestones,“ said Ralf Thomas, chair of the supervisory board of Siemens Healthineers AG. “I would warmly like to thank Philipp Rösler, Gregory Sorensen, Norbert Gaus and Andreas C. Hoffman, who will have completed their term next February, for their commitment to Siemens Healthineers and for serving in the very first supervisory board since the company’s initial public offering.”&nbsp;</p><p>The Siemens Healthineers supervisory board consists of 10 members. Eight members will complete their term on February 15, 2023. Four of those are nominated to renew their mandate:&nbsp;</p><ul><li>Ralf Thomas, chair of the supervisory board of Siemens Healthineers AG, member of the supervisory board of Siemens Energy AG, and Chief Financial Officer of Siemens AG&nbsp;</li><li>Marion Helmes, chair of the audit committee of Siemens Healthineers AG, vice chair of the supervisory board of ProSiebenSat.1 Media SE and member of the supervisory boards of Heineken N.V. and Lonza Group AG&nbsp;</li><li>Nathalie von Siemens, member of the supervisory board of Siemens AG, Messer SE &amp; Co. KGaA, TÜV SÜD AG, and EssilorLuxottica S.A.&nbsp;</li><li>Karl-Heinz Streibich, member of the supervisory boards of Deutsche Telekom AG, and Münchener Rückversicherungs-Gesellschaft AG</li></ul><p>Roland Busch, CEO of Siemens AG, joined the Supervisory Board in 2020 and Peer M. Schatz, managing director of PS Capital Management GmbH, joined in 2021. Their terms are due to expire at the end of the Annual Shareholder’s Meeting in 2025 and 2026, respectively.</p><p id="isPasted">For further information on the Siemens Healthineers Supervisory Board, please see <a href="/investor-relations/supervisory-board"></a></p>

Siemens Healthineers 2023

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies are continuously developing their product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2022, which ended on September 30, 2022, Siemens Healthineers, which has approximately 69,500 employees worldwide, generated revenue of around €21.7 billion and adjusted EBIT of almost €3.7 billion. Further information is available at